



(51) International Patent Classification:

A01N 43/02 (2006.01) *A61K 31/38* (2006.01)
A01N 43/22 (2006.01)

(21) International Application Number:

PCT/US2011/034024

(22) International Filing Date:

27 April 2011 (27.04.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/328,212 27 April 2010 (27.04.2010) US
61/329,225 29 April 2010 (29.04.2010) US

(71) Applicant (for all designated States except US): **GLAXOSMITHKLINE LLC** [US/US]; Global Patents, Five Moore Drive, C.2111.2F, Post Office Box 13398, Research Triangle Park, North Carolina 27709-3398 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AQUINO, Christopher Joseph** [US/US]; GlaxoSmithKline, c/o Global Patents, Five Moore Drive, C.2111.2F, PO Box 13398, Research Triangle Park, North Carolina 27709 (US). **COLLINS, Jon Loren** [US/US]; GlaxoSmithKline, c/o Global Patents, Five Moore Drive, C.2111.2F, PO Box 13398, Research Triangle Park, North Carolina 27709 (US). **COWAN, David John** [US/US]; GlaxoSmithKline, c/o Global Patents, Five Moore Drive, PO Box 13398, Research Triangle Park, North Carolina 27709 (US). **WU, Yulin** [CN/US]; GlaxoSmithKline, c/o Global Patents, Five Moore Drive, C.2111.2F, PO Box 13398, Research Triangle Park, North Carolina 27709 (US).

(74) Agent: **BRINK, Robert H.**; GlaxoSmithKline, c/o Global Patents, Five Moore Drive, C.2111.2F, PO Box 13398, Research Triangle Park, US 27709 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: CHEMICAL COMPOUNDS



(I)

(57) Abstract: Compounds of Formula (I) and methods for treating metabolic disorders are disclosed.